Comparison Of ER-Positive Versus ER-Negative In Breast Cancer Women And Invasive Ductal Carcinoma In The West Of Iran: A Direct Correlation With Vascular Invasion
Comparison Of ER-Positive Versus ER-Negative In Breast Cancer Women And Invasive Ductal Carcinoma
DOI:
https://doi.org/10.70284/njirm.v7i1.1041Keywords:
Breast cancer, Estrogen receptor, Vascular invasion, P53Abstract
Background & Objective: ER expression is the main indicator of potential responses to endocrine therapy,
and approximately 70% of human breast cancers are hormone-dependent and ER-positive. The aim of the study is to
evaluate the correlation between risk factors with ER status in breast cancer patients in the West of Iran.
Methodology: In a retrospective study, 260 breast cancer women were included invasive ductal carcinoma our Clinic.
A sufficient sample size was selected from any patient, and the slides were stained by hematoxylin and eosin (H & E)
method. Estrogen receptor (ER) and progesterone receptor (PR) positivity were defined as ≥10% positive tumor cells
with nuclear staining. Chi-square test and T-test were used to analyze the significance of correlation between the
expression of ER and other parameters. Results: The patients were divided into two groups (156 patients with ERpositive
group and 104 patients with ER-negative group). There was a significant difference between histological
grade, nuclear grade, lymph node metastasis, tumor size and vascular invasion and also tumor markers of HER2, PR,
P53 expression with ER status. Based on binary logistic regression analysis, in patients with ER-positive, more patients
had vascular invasion and PR-positive, but P53 was negative. Conclusion: There was a direct correlation between
vascular invasion and PR, with ER status and a reverse correlation between p53 with ER status. [Sadeghi M NJIRM
2016; 7 (1): 37-40]
References
Sadeghi E. Clinicopathology Figures of Breast Cancer
Women with Brain Metastasis and Invasive Ductal
Carcinoma. American Journal of Cancer
Prevention.2015; 3 (3), 68-71.
2. Joensuu K, Leidenius M, Kero M, Andersson LC,
Horwitz KB, Heikkilä P. ER, PR, HER2, Ki-67 and CK5
in Early and Late Relapsing Breast Cancer-Reduced
CK5 Expression in Metastases. Breast Cancer (Auckl).
2013;7:23-34.
3. Lumachi F, Brunello A, Maruzzo M, Basso U, Basso
SM. Treatment of estrogen receptor-positive breast
cancer. Curr Med Chem. 2013;20(5):596-604.
4. Kurbel S. Selective reduction of estrogen receptor
(ER) positive breast cancer occurrence by estrogen
receptor modulators supports etiological distinction
between ER positive and ER negative breast cancers.
Med Hypotheses. 2005;64(6):1182-7.
5. Sheikh MS, Garcia M, Pujol P, Fontana JA, Rochefort
H. Why are estrogen-receptor-negative breast
cancers more aggressive than the estrogenreceptor-
positive breast cancers? Invasion
Metastasis. 1994-1995;14(1-6):329-36.
6. Vousden KH, Prives C. Blinded by the light: the
growing complexity of p53. Cell.2009 137, 413–431.
7. Vinh-Hung V, Verschraegen C, Promish DI, Cserni G,
Van de Steene J, Tai P, et al. Ratios of involved
nodes in early breast cancer. Breast Cancer Res.
2004;6(6):R680-8. Epub 2004 Oct 6.
8. Cianfrocca M, Goldstein LJ. Prognostic and
predictive factors in early-stage breast cancer.
Oncologist. 2004;9(6):606-16.
9. Shahriari Ahmadi A, Mahdipour L, Payandeh M,
Sadeghi M. Epidemiology, Pathology and
Histochemistry Features in Women with Breast
Cancer. American Journal of Cancer Prevention.
2015;393):54-57.
10. Putti TC, El-Rehim DM, Rakha EA, Paish CE, Lee AH,
Pinder SE, et al. Estrogen receptor-negative breast
carcinomas: a review of morphology and
immunophenotypical analysis. Mod Pathol. 2005
Jan;18(1):26-35.
11. Berger CE, Qian Y, Liu G, Chen H, Chen X. p53, a
target of estrogen receptor (ER) α, modulates DNA
damage-induced growth suppression in ER-positive
breast cancer cells. J Biol Chem. 2012 Aug
31;287(36):30117-27.
12. Pharoah PD, Day NE, Caldas C. Somatic mutations in
the p53 gene and prognosis in breast cancer: a
meta-analysis. Br J Cancer. 1999;8:1968–1973.
13. Horiguchi J, Koibuchi Y, Iijima K, Yoshida T, Yoshida
M, Takata D, et al. Immunohistochemical double
staining with estrogen receptor and HER2 on
primary breast cancer. Int J Mol Med. 2003;12:855–
859.
14. Shapochka DO, Zaletok SP, Gnidyuk MI. Relationship
between NF-κB, ER, PR, Her2/neu, Ki67, p53
expression in human breast cancer. Exp Oncol. 2012
Dec;34(4):358-63.
15. Hlgreno J, Tal L, Estman G, Nesson L-G. Prediction of
axillary lymph node metastases in screened breast
cancer population. Acta Oncol. 1994;33(6):603–608.
16. Wang B, Wang X, Wang J, Xuan L, Wang Z, Wang X,
et al. [Expression of Ki67 and clinicopathological
features in breast cancer]. Zhonghua Zhong Liu Za
Zhi. 2014 Apr;36(4):273-5.
17. Ashturkar AV, Pathak GS, Deshmukh SD, Pandave
HT. Factors predicting the axillary lymph node
metastasis in breast cancer: is axillary node
clearance indicated in every breast cancer patient?:
factors predicting the axillary lymphnode
metastases in breast cancer. Indian J Surg. 2011
Oct;73(5):331-5. Epub 2011 May 24.
18. Viale G, Zurrida S, Maiorano E, Mazzarol G, Pruneri
G, Paganelli G, et al. Predicting the status of axillary
sentinel lymph nodes in 4351 patients with invasive
breast carcinoma treated in a single institution.
Cancer. 2005;103:492–500.
19. Bonneterre J, Peyrat JP, Beuscart R, Demaille A.
Correlation between prolactin receptors (PRL R),
estradiol (ER) and progesterone receptors (PgR) in
human breast cancer. Eur J Cancer Clin Oncol. 1986
Nov;22(11):1331-6.
